文献速递血管炎

巨细胞动脉炎停用托珠单抗后的复发风险

Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

研究评估巨细胞动脉炎患者接受52周托珠单抗治疗后停药,20例中17例达持续缓解,平均随访28.1个月后8例复发,平均复发时间6.3个月(6例在5个月内)。复发者更年轻且MRA管壁强化更明显,但血清生物标志物无法提示亚临床活动。

要点

  • 52周托珠单抗治疗后半数患者停药后维持持续缓解
  • 8/17例持续缓解者停药后复发,多发生在5个月内
  • 复发者更年轻且MRA管壁强化更明显,但无可靠预测因素

核心结论

  • 52周托珠单抗治疗可诱导持续缓解,但停药后约半数持续缓解患者复发。
  • 临床、血清学和MRA指标均不能预测复发。

研究设计与样本

  • 评估托珠单抗治疗组中完成52周治疗的全部患者。
  • 持续缓解者行MRA并检测血清生物标志物。

主要发现

  • 20例中17例在第52周无合并用药下达持续缓解。
  • 停药后平均随访28.1个月(范围17-44),8例复发,平均复发时间6.3个月(范围2-14),其中6例在5个月内。
  • 复发者更年轻且MRA管壁强化更明显,所有受试者MRA均显示低强度管壁信号,无主动脉瘤形成。
  • 血清IL-6、MMP-3、sTNFR2、sCD163、sICAM-1和Pentraxin-3水平与匹配健康对照无差异。

临床怎么用

  • 停用托珠单抗后需密切监测复发,尤其是停药后前5个月。

局限性

  • 样本量小(20例),随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, the biologic agent was stopped after 52 weeks. We therefore studied what proportion of patients relapsed, when relapses occurred and whether factors might predict relapse after tocilizumab treatment discontinuation. METHODS: All patients in the tocilizumab arm who had received a 52-week treatment were evaluated. In case of lasting remission, magnetic resonance angiography (MRA) was performed and sera were taken to search for biomarkers associated with subclinical disease activity. RESULTS: Seventeen of 20 patients randomized to the tocilizumab treatment arm were in lasting remission without any co-medication at week 52. Mean follow-up after study end was 28.1 months (range 17-44). Eight patients relapsed after a mean of 6.3 months (range 2-14) (six within the first 5 months, two patients at months 13 and 14, respectively). Relapsing patients were younger and showed more signs of mural enhancement in MRA compared with non-relapsing patients. MRA documented low-intensity vessel wall signals in all subjects. No morphological changes such as formation of aneurysm of aorta occurred. Biomarkers in sera did not indicate subclinical disease activity: levels of IL-6, MMP-3, soluble TNF receptor 2, soluble CD163, soluble intercellular adhesion molecule-1 and Pentraxin-3 did not differ from matched healthy controls. CONCLUSION: The data show that a 52-week treatment with tocilizumab induces a lasting remission that persists in half of the patients after treatment stop. None of the clinical, serological or MRA findings qualify to predict relapse. Remarkably, MRA revealed a persisting wall enhancement of the descending aorta.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Adler S, Reichenbach S, Gloor A, et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford). 2019. PMID: 30915462. doi:10.1093/rheumatology/kez091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。